SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients

The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies

Lonza to sell capsules & health ingredients business for $3 billion in major strategic shift

Roche’s Gazyva shows breakthrough results in Lupus phase III trial

Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile

Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial

The company announced positive topline data from the Phase II ZUPREME-1 trial

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations

argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis

The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4

Lonza to set up Global Capability Centre in Hyderabad

Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park

The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant